New Protein A Device Set To Redefine Biomanufacturing

The biomanufacturing industry has long envisioned fully single-use facilities to improve efficiency and scalability, and with the introduction of the Gore Protein A Membrane Device, that vision is now a reality. This groundbreaking solution tackles scalability challenges in membrane-based chromatography, enabling end-to-end single-use manufacturing processes.

Unlike traditional resins, the Gore Protein A Membrane Device excels at affinity capturing for antibody-based therapies, offering faster cycling times and significantly higher productivity, thus transforming the production process. When integrated with AGC Biologics' monoclonal antibody production platform, it provides a fast-track, cost-effective solution for antibody production. AGC Biologics has successfully demonstrated that resin-based and membrane-based technologies offer equivalent product quality, while the Gore device provides a pioneering alternative for the industry.

Explore how the collaboration between AGC Biologics and Gore can enhance efficiency, flexibility, and innovation in your manufacturing processes.

The benefits of the Gore Protein A device span the entire development pipeline, from discovery to GMP-level production. In early stages, the device accelerates molecule screening, speeding up the identification of next-generation therapies. This speed and adaptability carry over through process development and clinical phases, transforming how therapies reach the market. Furthermore, the device improves facility design by offering better bioburden control and enabling flexible batch sizing. Manufacturers can scale up without the need for larger columns, instead using the same device or multiple units, simplifying the process.

With its unmatched advantages, the Gore Protein A Membrane Device is set to revolutionize biomanufacturing and drive therapeutic innovation forward.